Oyster Point Pharmaceuticals Inc. is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapies to treat ocular surface disease.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 11/08/17 | $22,000,000 | Series A |
Versant Ventures | undisclosed |
| 02/26/19 | $93,000,000 | Series B |
Falcon Vision Flying L Partners INVUS Opportunities New Enterprise Associates Versant Ventures Vida Ventures | undisclosed |
